Trial Profile
Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Tretinoin (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 11 Sep 2023 Status changed from active, no longer recruiting to completed.
- 03 Sep 2020 Planned End Date changed from 1 Mar 2020 to 1 Jan 2025.
- 01 May 2018 Planned primary completion date changed from 1 Mar 2019 to 1 Dec 2018.